Amicus Therapeutics Inc (FOLD)
Official siteBIOTECHNOLOGY
Last updated: Apr 27, 2026 at 5:00 PM ET
Amicus Therapeutics Inc (FOLD) Financials: Revenue, Profit and Cash Flow
Amicus Therapeutics reported revenue of $634.21M for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was -$27.11M with a net margin of -4.3%, operating cash flow was $33.15M and free cash flow was $29.85M. The quarter ended Dec 31, 2025 had revenue of $185.21M and net income of $1.69M.
Revenue and Margins
The operating margin was 5.2% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $4.96M, a compound annual rate of 71.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $634.21M | +20.0% | 88.5% | 5.2% | -4.3% |
| Dec 2024 | $528.29M | +32.3% | 90.0% | 4.7% | -10.6% |
| Dec 2023 | $399.36M | +21.3% | 90.7% | -19.3% | -38.0% |
| Dec 2022 | $329.23M | +7.8% | 88.3% | -64.4% | -71.9% |
| Dec 2021 | $305.51M | +17.1% | 88.7% | -67.6% | -82.0% |
| Dec 2020 | $260.89M | +43.2% | 88.1% | -94.7% | -106.1% |
| Dec 2019 | $182.24M | +99.7% | 87.9% | -166.8% | -195.6% |
| Dec 2018 | $91.25M | +147.1% | 84.2% | -360.3% | -382.5% |
| Dec 2017 | $36.93M | +644.9% | 83.1% | -1196.8% | -769.0% |
| Dec 2016 | $4.96M | N/A | 83.2% | -3668.6% | -4034.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income fell 88.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $634.21M | $528.29M | $399.36M | $329.23M | $305.51M | $260.89M | $182.24M | $91.25M | $36.93M | $4.96M |
| Cost of revenue | $72.93M | $52.94M | $37.33M | $38.60M | $34.47M | $31.04M | $21.96M | $14.40M | $6.24M | $833.00K |
| Gross profit | $561.28M | $475.35M | $362.03M | $290.63M | $271.05M | $229.84M | $160.27M | $76.84M | $30.69M | $4.13M |
| Research and development | $135.84M | $109.36M | $152.38M | $276.68M | $272.05M | $308.44M | $286.38M | $270.90M | $149.31M | $104.79M |
| Operating income | $32.79M | $24.88M | -$77.21M | -$212.12M | -$206.43M | -$247.00M | -$304.04M | -$328.78M | -$441.99M | -$181.89M |
| Net income | -$27.11M | -$56.11M | -$151.58M | -$236.57M | -$250.46M | -$276.85M | -$356.39M | -$349.00M | -$284.00M | -$200.04M |
| EBITDA | $53.06M | $26.24M | N/A | -$199.97M | -$200.64M | -$244.41M | N/A | -$322.47M | -$422.68M | N/A |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $185.21M | $169.06M | $154.69M | $125.25M | $149.71M | $141.52M | $126.67M | $110.40M | $115.08M | $103.50M | $94.50M | $86.27M |
| Gross profit | $158.66M | $149.59M | $139.47M | $113.55M | $134.87M | $128.24M | $115.41M | $96.84M | $103.76M | $93.56M | $85.39M | $79.33M |
| Operating income | $15.95M | $34.27M | -$9.47M | -$7.95M | $15.97M | $21.66M | $14.97M | -$27.72M | -$3.69M | -$17.02M | -$18.86M | -$37.64M |
| Net income | $1.69M | $17.31M | -$24.42M | -$21.69M | $14.74M | -$6.73M | -$15.70M | -$48.42M | -$33.84M | -$21.58M | -$43.23M | -$52.93M |
Balance Sheet
As of Dec 2025, total debt of $401.40M exceeded cash and equivalents by $187.39M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $949.87M | $785.03M | $777.88M | $724.17M | $905.14M | $886.52M | $850.21M | $789.95M | $627.02M | $1.04B |
| Current assets | $676.17M | $504.74M | $483.06M | $423.82M | $596.83M | $579.47M | $520.07M | $551.10M | $391.96M | $340.06M |
| Cash and equivalents | $214.01M | $213.75M | $246.99M | $148.81M | $245.20M | $163.24M | $142.84M | $79.75M | $49.06M | $187.03M |
| Total liabilities | $675.63M | $590.99M | $617.71M | $601.12M | $597.77M | $600.14M | $373.78M | $447.04M | $274.17M | $676.69M |
| Short-term debt | $8.74M | $8.46M | $8.32M | $21.42M | $18.90M | $8.90M | $0 | N/A | $8.40M | $56.10M |
| Long-term debt | $392.66M | $390.11M | $387.86M | $391.99M | $389.36M | $389.25M | $149.50M | $321.74M | $164.17M | $154.46M |
| Shareholder equity | $274.24M | $194.04M | $160.17M | $123.05M | $307.37M | $286.38M | $476.43M | $342.91M | $352.85M | $360.15M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $949.87M | $868.81M | $815.30M | $789.84M | $785.03M | $786.56M | $749.48M | $721.79M | $777.88M | $764.08M | $730.09M | $700.52M |
| Total liabilities | $675.63M | $638.39M | $611.00M | $596.28M | $590.99M | $607.73M | $616.96M | $591.10M | $617.71M | $630.85M | $618.51M | $597.95M |
| Cash and equivalents | $214.01M | $190.55M | $158.70M | $181.66M | $213.75M | $233.65M | $209.34M | $209.76M | $246.99M | $263.32M | $211.31M | $160.60M |
| Shareholder equity | $274.24M | $230.42M | $204.30M | $193.56M | $194.04M | $178.82M | $132.52M | $130.69M | $160.17M | $133.24M | $111.58M | $102.57M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 90.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $33.15M | -$33.89M | -$69.09M | -$166.57M | -$202.49M | -$233.29M | -$250.42M | -$299.95M | -$213.69M | -$150.15M |
| Capital expenditures | $3.30M | $3.55M | $7.44M | $3.77M | $3.88M | $3.23M | $20.01M | $6.31M | $4.53M | $5.95M |
| Free cash flow | $29.85M | -$37.44M | -$76.53M | -$170.34M | -$206.38M | -$236.52M | -$270.43M | -$306.26M | -$218.22M | -$156.10M |
| Dividends paid | N/A | N/A | N/A | $4.31M | $15.01M | $32.25M | $3.23M | N/A | $0 | $0 |
| Investing cash flow | -$46.43M | -$560.00K | $98.06M | $92.32M | $78.76M | -$13.58M | $95.15M | -$121.20M | -$171.24M | -$4.51M |
| Financing cash flow | $610.00K | $5.12M | $61.68M | -$7.46M | $212.07M | $262.86M | $217.50M | $450.77M | $247.43M | $272.71M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $16.25M | $35.66M | -$26.53M | $7.76M | -$3.92M | -$22.97M | $22.69M | -$29.70M | $3.46M | -$38.35M | -$16.13M | -$18.07M |
| Capital expenditures | $299.00K | $382.00K | $2.40M | $212.00K | $288.00K | $266.00K | $1.19M | $1.81M | $1.73M | $1.56M | $2.20M | $1.94M |
| Free cash flow | $15.95M | $35.28M | -$28.93M | $7.55M | -$4.20M | -$23.24M | $21.50M | -$31.51M | $1.73M | -$39.91M | -$18.34M | -$20.01M |
Frequently Asked Questions About FOLD
What is Amicus Therapeutics' annual revenue?
Amicus Therapeutics reported revenue of $634.21M for the fiscal year ended Dec 31, 2025.
How fast is Amicus Therapeutics' revenue growing?
Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.4%.
Is Amicus Therapeutics profitable?
No. Amicus Therapeutics reported net income of -$27.11M for the fiscal year ended Dec 31, 2025, with a net margin of -4.3%.
How much free cash flow does FOLD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $33.15M minus capital expenditures of $3.30M produced free cash flow of $29.85M.
How much debt does Amicus Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $392.66M, short-term debt of $8.74M and cash and equivalents of $214.01M.
FOLD pages: Overview, Financials